Massive share issuance will likely pressure the stock price due to immediate overhang. The warrants (24M Series C at $0.50) add further potential dilution. Monitor for any Nasdaq compliance update and note the 90-day lock-up expiration date in mid-August 2026 as a potential catalyst for further selling.
Executive Summary
Sunshine Biopharma has completed a $6.0 million priced offering, issuing 11,160,000 Common Units (each with one share of common stock and two Series C warrants) and 840,000 Pre-Funded Units at $0.50 per unit. The offering more than triples the share count from 5,005,945 to 17,005,945, creating massive dilution of approximately 240% relative to pre-offering shares outstanding. Net proceeds of ~$5.0 million will go to general working capital.
Key Financial Metrics
Key Facts
- Public offering price: $0.50 per Common Unit (vs. $0.51 last sale on May 18, 2026 — a ~2% discount)
- 11,160,000 Common Units and 840,000 Pre-Funded Units sold for total gross proceeds of $6,000,000
- Shares outstanding pre-offering: 5,005,945; post-offering: 17,005,945 — a 240% increase in share count
- Series C Warrants: 24,000,000 warrants with $0.50 exercise price, 5-year term, exercisable immediately
- Pre-Funded Warrants: 840,000 warrants with $0.00001 exercise price, no expiration
- Placement agent: Aegis Capital Corp.; fees of $420,000 (7% of gross) plus 2% non-accountable expense allowance
- 90-day lock-up on executive officers and directors; 90-day standstill on the company
- Net proceeds estimated at ~$5.0 million for general corporate purposes/working capital
- Stock trades at ~$0.51 near the $1.00 min bid price Nasdaq compliance threshold; risk of delisting noted
Financial Impact
Immediate dilution of ~240% from pre-offering shares outstanding; $6M gross raised at $0.50/unit
Risk Factors
- Extreme dilution of 240% from share count increase alone, without considering warrant exercise
- Nasdaq minimum bid price compliance risk — stock trades near $0.51 vs $1.00 requirement
- Potential further dilution from 24M Series C warrants (at $0.50) and 840K pre-funded warrants
- Company has broad discretion on use of proceeds; no specific allocation stated
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001683168-26-004098 |
| Document: 0001683168-26-004098-index-headers.html | 0001683168-26-004098 |
| Document: 0001683168-26-004098-index.html | 0001683168-26-004098 |
| Document: 0001683168-26-004098.txt | 0001683168-26-004098 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 19, 2026 22w ago | 424B4 | $0.0851 $0.0648 | ▲ +23.85% | ▲ +24.84% | — |
Apr 9, 2026 28w ago | 8-K | $0.0851 $0.0851 | · 0.00% | ▼ −8.53% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers